REG - Novacyt S.A. - Reminder to shareholders re. AGM voting

Novacyt SAAnnouncement

28/09/2023 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230928:nRSb0456Oa&default-theme=true

RNS Number : 0456O  Novacyt S.A.  28 September 2023

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Reminder to shareholders re. AGM voting

 

Paris, France and Eastleigh, UK - 28 September 2023 - Novacyt (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical
diagnostics, will be holding its annual general meeting (AGM) exclusively as
an open online meeting at 1pm BST/2pm CEST on Thursday, 5 October 2023. As
usual, and in accordance with French corporate law, the AGM comprises both
ordinary and extraordinary resolutions. All materials can be found at
www.novacyt.com/investors (http://www.novacyt.com/investors) .

 

The Board would like to strongly encourage shareholders to submit their votes
in advance, in accordance with the instructions in the Notice of the AGM. As
this is a rescheduled meeting, all previous votes are now void and all
shareholders must resubmit their votes.

 

Under French law, for the AGM and EGM meetings to be quorate at the first
attempt, shareholders representing at least 20% of the share capital and
voting rights, on ordinary resolutions, and 25% of the share capital and
voting rights, on extraordinary resolutions, must be present, represented or
have voted in advance under the conditions set out below.

 

Shareholders can vote in advance of the AGM by:

 

·     Downloading a copy of the proxy voting form from the website
www.novacyt.com/investors (http://www.novacyt.com/investors) , completing it
and returning it together with evidence of their shareholding which must be in
the form of a share certificate (attestation), either by post to the following
address: 6 avenue de Provence 75452 Paris Cedex 09, or via email to the
following address: serviceproxy@cic.fr (mailto:serviceproxy@cic.fr) , or
investor.relations@novacyt.com (mailto:investor.relations@novacyt.com) , no
later than 2 October 2023 inclusive.

·     Voting on-line using the Votaccess portal
http://www.actionnaire.cic-marketsolutions.eu
(http://www.actionnaire.cic-marketsolutions.eu)  if securities held on
Euronext Growth are registered with any of the following banks: CIC, Natixis,
Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse
Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank,
Bank of New York or JP Morgan. The Votaccess portal is open until 4 October
2023 2pm BST/3pm CEST.

·     Voting on-line via a broker, nominee, bank or authorised
intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are
now using the Broadridge ProxyVote on-line voting portal.

 

Shareholders can register for the AGM and access the online meeting by
visiting https://novacytagm23.eventcaster.co.uk
(https://novacytagm23.eventcaster.co.uk) . Registration must be accompanied by
formal evidence of shareholding. As this is a rescheduled meeting, all
previous registrations are now void and all shareholders must re-register.

 

Following registration approval, shareholders will be able to virtually attend
the AGM and vote online during the meeting if they wish, providing formal
evidence of holding has been provided prior to the meeting.

 

Shareholders who have voted (through a proxy, via their broker, nominee, bank,
authorised intermediary, Votaccess portal or Broadridge ProxyVote) will be
allowed to attend the AGM online but will not be able to vote twice.

 

Following the meeting, a recording of the AGM will be available on the
Company's website at www.novacyt.com/investors
(http://www.novacyt.com/investors) .

 

Contacts

 

 Novacyt SA                                            +44 (0) 20 7756 1300
 James Wakefield, Non-Executive Chairman

 James McCarthy, Acting Chief Executive Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                       +44 (0)20 3470 0470

 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Numis (Joint Broker)                                                                +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Jack McLaren

 Allegra Finance (French Listing Sponsor)                                             +33 (1) 42 22 10 10

                                                                                   r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                                                       y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                       +44 (0)20 7933 8780

 Paul McManus / Stephanie Cuthbert / Anna Dunphy       novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio
of in vitro and molecular diagnostic tests for a wide range of infectious
diseases, enabling faster, more accurate, accessible testing to improve
healthcare outcomes. The Company provides customers with a seamless
sample-to-result workflow using its integrated and scalable
instrumentation/solutions. The Company specialises in the design, manufacture,
and supply of real-time PCR kits, reagents and a full range of laboratory and
qPCR instrumentation for molecular biology research and clinical use. Novacyt
offers one of the world's most varied and comprehensive range of qPCR assays,
covering human, veterinary, biodefence, environmental, agriculture and food
testing.

 

The acquisition of Yourgene in September 2023 added a complementary
international genomics technology and services business, focussed on
delivering accurate molecular diagnostic and screening solutions, across
reproductive health and precision medicine. Yourgene's portfolio of in vitro
diagnostic products includes non-invasive prenatal tests (NIPT) for Down's
Syndrome and other genetic disorders, Cystic Fibrosis screening tests,
invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also
works in partnership with global leaders in DNA technology to allow its
Ranger® Technology to deliver dynamic target enrichment.

 

Novacyt is headquartered in Vélizy in France with offices in the UK in
Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei
(divestment pending), Singapore, the US and Canada and is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext
Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUWSOROWUKUAR